Page 3 - Pruritus Numerical Rating Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evelo Biosciences, Inc.: Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis
physician-reported outcomes -
-Improvements in patient-reported outcomes in DLQI and POEM, including itch-
-EASI50 benchmark reached in 44% of patients treated with EDP1815 compared to 0% in placebo group at day 70-
-Phase 2 atopic dermatitis trial initiation in 3Q 2021-
-Management to host conference call at 8:30 a.m. ET today with Dr. Benjamin Ehst-
CAMBRIDGE, Mass., Jan. 20, 2021interim data in 23 evaluable patients. These new results now include patient-reported outcomes, as well as all of the physician-reported outcomes for all 24 patients in the cohort. The primary endpoint of the Phase 1b trial was safety and tolerability. EDP1815 was well tolerated in this study with no treatment-related adverse events of moderate or severe intensity, and no serious adverse events. ....

United Kingdom , United States , Evelo Biosciences , Jessica Cotrone , Kostenloser Wertpapierhandel , Benjamin Ehst , Douglas Maslin , Oregon Medical Research Center , Dermatology Life Quality Index , Patient Oriented Eczema Measure , Pruritus Numerical Rating Scale , Atopic Dermatitis , Global Assessment , Eczema Area , Severity Index , Body Surface Area , Placebo Percentage Change , Least Squares Mean Percentage Change From , Pharmacology Physician , Immunology Clinical Lead , Board Certified Dermatologist , Clinical Associate Professor , Private Securities Litigation Reform Act , Quarterly Report , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் ,